Esperion Therapeutics, Inc. 8-K Filing
Ticker: ESPR · Form: 8-K · Filed: Nov 4, 2025 · CIK: 1434868
| Field | Detail |
|---|---|
| Company | Esperion Therapeutics, Inc. (ESPR) |
| Form Type | 8-K |
| Filed Date | Nov 4, 2025 |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.001, $535,000, $35,000 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Esperion Therapeutics, Inc. (ticker: ESPR) to the SEC on Nov 4, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ich registered Common Stock, par value $0.001 per share ESPR NASDAQ Stock Market LLC); $535,000 (is entitled to an annual base salary of $535,000. Mr. Harlow is also eligible to be cons); $35,000 (lso receive a one-time sign on bonus of $35,000. Mr. Harlow is eligible to participate).
How long is this filing?
Esperion Therapeutics, Inc.'s 8-K filing is 5 pages with approximately 1,543 words. Estimated reading time is 6 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 1,543 words · 6 min read · ~5 pages · Grade level 10.8 · Accepted 2025-11-04 08:49:31
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share ESPR NASDAQ Stock Market LLC
- $535,000 — is entitled to an annual base salary of $535,000. Mr. Harlow is also eligible to be cons
- $35,000 — lso receive a one-time sign on bonus of $35,000. Mr. Harlow is eligible to participate
Filing Documents
- espr-20251104.htm (8-K) — 34KB
- exhibit101harlowesperionex.htm (EX-10.1) — 86KB
- exhibit991esperionappoints.htm (EX-99.1) — 13KB
- 0001628280-25-048557.txt ( ) — 273KB
- espr-20251104.xsd (EX-101.SCH) — 2KB
- espr-20251104_lab.xml (EX-101.LAB) — 22KB
- espr-20251104_pre.xml (EX-101.PRE) — 13KB
- espr-20251104_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On November 4, 2025, the Company issued a press release announcing the appointment of Mr. Harlow as the Company's Chief Commercial Officer. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 7.01 by reference. The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. Exhibit No. Description 10.1 Employment Agreement, effective as of November 17, 2025, by and between Esperion Therapeutics, Inc. and John Harlow. 99.1 Press Release dated November 4, 2025. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 4, 2025 Esperion Therapeutics, Inc. By: /s/ Sheldon L. Koenig Sheldon L. Koenig President and Chief Executive Officer